Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Alaunos Therapeutics (TCRT) Revenue (2016 - 2025)

Historic Revenue for Alaunos Therapeutics (TCRT) over the last 13 years, with Q1 2025 value amounting to $2000.0.

  • Alaunos Therapeutics' Revenue rose 10000.0% to $2000.0 in Q1 2025 from the same period last year, while for Sep 2025 it was $6000.0, marking a year-over-year change of 0.0%. This contributed to the annual value of $10000.0 for FY2024, which is 10000.0% up from last year.
  • As of Q1 2025, Alaunos Therapeutics' Revenue stood at $2000.0, which was up 10000.0% from $4000.0 recorded in Q4 2024.
  • Over the past 5 years, Alaunos Therapeutics' Revenue peaked at $2.9 million during Q3 2022, and registered a low of $1000.0 during Q4 2023.
  • Its 5-year average for Revenue is $333800.0, with a median of $4000.0 in 2023.
  • In the last 5 years, Alaunos Therapeutics' Revenue skyrocketed by 63140.7% in 2022 and then tumbled by 9090.91% in 2023.
  • Alaunos Therapeutics' Revenue (Quarter) stood at $2000.0 in 2021, then surged by 450.0% to $11000.0 in 2022, then plummeted by 90.91% to $1000.0 in 2023, then soared by 300.0% to $4000.0 in 2024, then tumbled by 50.0% to $2000.0 in 2025.
  • Its Revenue was $2000.0 in Q1 2025, compared to $4000.0 in Q4 2024 and $4000.0 in Q2 2024.